Blockchain Registration Transaction Record

VERAXA Biotech Begins Cell Line Development for BiTAC-TCE Program with ATUM

VERAXA Biotech initiates cell line development for BiTAC-TCE program with ATUM, using Leap-In Transposase technology. Platform aims to improve tumor selectivity and reduce toxicity in cancer immunotherapy. Learn more.

This development is crucial because VERAXA's conditional "AND"-gated BiTAC-TCE platform aims to reduce off-tumor toxicity—a major limitation of conventional T-cell engagers—potentially enabling safer and more effective cancer immunotherapies. The collaboration with ATUM to generate stable cell lines is a key step toward clinical trials, bringing this innovative approach closer to patients who need better treatment options with fewer side effects.